CAMBRIDGE, Mass. — Alkeus Pharmaceuticals, Inc., a biopharmaceutical company focused on preserving the sight of individuals affected by retinal diseases, has announced that Michel Dahan, President and Chief Executive Officer, will provide a corporate update and present the latest clinical study results for the company’s investigational oral therapy aimed at preventing blindness in patients with Stargardt disease. This presentation is scheduled for the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
Presentation Details:
- Date: Tuesday, January 14
- Time: 4:30 p.m. PST
- Location: The Westin St. Francis San Francisco, Mission Bay room, 32nd floor of the Tower Building
About Alkeus Pharmaceuticals:
Alkeus Pharmaceuticals, Inc., headquartered in Cambridge, Mass., is a private biopharmaceutical company backed by institutional investors led by Bain Capital Life Sciences. Since its founding in 2010, Alkeus has been dedicated to developing therapies for serious eye diseases with high unmet needs, particularly those affecting the retina. The company’s lead candidate, gildeuretinol acetate (ALK-001), is a new chemical entity currently under evaluation in clinical trials for treating Stargardt disease and geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
About Gildeuretinol Acetate (ALK-001):
Gildeuretinol acetate is designed to reduce the dimerization of vitamin A without affecting the visual cycle. Preclinical studies have shown that gildeuretinol can decrease vitamin A dimerization to normal rates, preventing retinal degeneration and loss of visual function in animal models of Stargardt disease. Clinical trials, including TEASE-1, have demonstrated significant slowing of retinal lesion growth in late-stage Stargardt patients over two years. Ongoing trials (TEASE-2, TEASE-3, and TEASE-4) continue to explore its efficacy. Gildeuretinol has received multiple designations from the U.S. Food and Drug Administration, including Breakthrough Therapy and Orphan Drug status for Stargardt disease. Additionally, the SAGA study in patients with GA secondary to AMD showed a meaningful trend in reducing lesion growth rate and improving low luminance visual acuity, alongside a favorable safety and tolerability profile.
